Cell & Gene Therapy Insights

Cell & Gene Therapy Insights 2026; 12(6), 563–575 DOI: 10.18609/cgti.2026.070 “...anticipate unexpected questions, take a hard look at your data, and try to assemble some experts to pick it apart before submission.” Early analytical decisions in cell therapy can influence the entire development pathway, from IND readiness and CDMO transfer to BLA submission and commercial scale‑up.

As iPSC-derived cell therapies progress through clinical development, sessions at the summit will examine first-in-human experiences and advancing data across Parkinson's disease and ocular indications, with a focus on safety, engraftment, durability, and functional outcomes. Ron Cohen (Chief Executive Officer, Oryon Cell Therapies) will offer an inside look at how Oryon is advancing autologous iPSC-derived dopaminergic neurons in Parkinson's disease.

Next-generation armored CAR-T cells — engineered with IL-12, PD-L1 blockade, and oncolytic virus antigen delivery — offer new strategies to overcome the immunosuppressive solid tumor microenvironment.

What you will learn 01 Why the −1 °C/min benchmark only holds within controlled-rate systems with active phase transition management – not in static freezers that happen to reach the same rate 02 How phase transition control reduces variability ~14-fold vs static freezing (CV 2.3% vs 32.6%), and why this interval is the period of greatest osmotic and mechanical stress on cells 03 How plate-based and cryogenic LN2 freezing systems with user-defined recipes deliver reproducible, high-viability...

What you will learn 01 How a precompetitive consortium can standardize shared domains – referral criteria, accreditation, registry architecture – while preserving sponsor-specific CMC and proprietary procedures 02 How a two-tier delivery network (Tier 1 regional hubs and Tier 2 accredited satellite centres) supported by tele-proctoring can expand procedural capacity equitably 03 How parallel regulatory engagement, outcomes-based reimbursement, workforce credentialing, and a mandatory registry...

Advanced tools and scientific breakthroughs are making the word 'undruggable' obsolete, while human-centered deal-making and innovative business models are set to dominate the coming years in the pharmaceutical industry. UK Biotech Day 2026 takes place at a time of real structural pressure across the life sciences sector.

Please note all fields marked with an * are mandatory Registering provides unlimited access to our library of articles, webinars, and industry insights from all our journals and creates a free BioInsights membership. By submitting this form, I agree to receive communications from BioInsights about published articles, webinars, and industry insights. I can unsubscribe at any time.

“I am hopeful that we will see more clinical applications of both viral and non‑viral gene‑writing approaches delivering therapeutic outcomes in the years to come.” Abi Pinchbeck, Editor, Cell & Gene Therapy Insights , speaks with Hao Wu, co-founder and CSO of Full Circles Therapeutics, about the evolving landscape of non‑viral delivery in cell and gene therapy, the development of the INSTALL platform for immune‑evasive kilobase gene writing, and the outlook for non‑viral approaches as...

Cell and Gene Therapy Insights 2026; 12(4), 492–501 10.18609/cgti.2026.056 Cell therapy manufacturing is evolving beyond manual open workflows, demanding closed, automated, and modular solutions to achieve scalability, consistency, and regulatory compliance.

Jude Samulski, Alumni Distinguished Professor, UNC Gene Therapy Center Jude Samulski’s Founders Award acceptance was a characteristically direct reflection on nearly five decades of AAV biology, and a candid assessment of where the field still has work to do. His central message: only 3% of AAV9 crosses the blood–brain barrier, and that figure demands a rethink.